AKT1 and cancer: Research has demonstrated that PI3K/Akt signaling pathway cascade inhibitors are among the most effective therapeutic strategies for treating cancer, whether used alone or in combination with other therapies.[32] Therefore, our findings suggest that targeting the PI3K-AKT signaling pathway and regulating ECM components and density could be a promising approach for effectively treating TGCT subtypes with better prognosis.